Alpha Teknova, Inc. - TKNO STOCK NEWS

Alpha Teknova reported a total revenue of $11.7 million for Q2 2022, representing a 41% year-over-year increase. The company maintains a cash position of $64.7 million to support ongoing growth investments and has adjusted its 2022 revenue outlook to $38-42 million. Although they experienced healthy demand, Teknova acknowledges potential revenue slowdown in H2 2022 due to biopharma customers deferring purchases. Gross profit reached $5.2 million, with a 44.9% gross margin, despite increased operating expenses of $11.9 million and a net loss of $6.2 million.

HOLLISTER, Calif., Aug. 01, 2022 – Alpha Teknova, Inc. (Nasdaq: TKNO) announced it will report its financial results for Q2 2022 on August 10, 2022, after market close. A conference call and webcast will follow at 4:30 p.m. ET. Teknova specializes in providing critical reagents for drug therapies, vaccines, and diagnostics, aiming to expedite clinical breakthroughs with a focus on custom solutions and fast delivery. Its products are essential across various applications, including cell and gene therapy and mRNA therapeutics.

Alpha Teknova, a provider of critical reagents for drug therapies and molecular diagnostics, will participate in the William Blair 42nd Annual Growth Stock Conference from June 6 to 9, 2022, in Chicago, IL. CEO Stephen Gunstream and CFO Matt Lowell will present on June 8 at 4:20 p.m. ET, discussing the company’s highlights, product portfolio, and market opportunities. A live audio webcast will be available on their Investor Relations website for 90 days post-event.

In Q1 2022, Teknova reported total revenue of $11.1 million, a 23% increase year-over-year. Excluding Sample Transport revenue, the increase was 37%. The company achieved a cash position of $76.5 million, supporting its growth strategy and expansion efforts, including a new manufacturing facility expected to be operational by year-end. However, the company reported a net loss of $5.5 million and operating expenses that rose to $11.2 million, reflecting increased hiring and public company costs. The 2022 revenue outlook anticipates $45 million to $48 million.

Alpha Teknova, Inc. (TKNO) will announce its Q1 financial results for the period ending March 31, 2022, on May 11, 2022. A conference call and webcast will occur at 4:30 p.m. ET the same day. The call can be accessed via the Investor Relations section of Teknova's website or by dialing dedicated numbers for domestic and international participants. Teknova specializes in providing critical reagents to support drug therapies, vaccines, and diagnostics, emphasizing customized products for accelerated clinical breakthroughs.

Teknova reported total revenue of $36.9 million for 2021, marking an 18% increase from 2020. Excluding Sample Transport revenue, the total was $35.4 million, up 31%. The fourth quarter revenue was $10.1 million, consistent with 2020, and 26% higher at $9.6 million when excluding Sample Transport. However, the net loss for 2021 was $9.8 million, or $0.61 per diluted share, a decline from 2020's net income. Looking ahead, Teknova projects revenue between $44 million and $48 million for 2022, driven by growth in Lab Essentials and Clinical Solutions.

Alpha Teknova (Nasdaq: TKNO) has announced it will report its financial results for the fourth quarter and full year 2021 on March 15, 2022, after market close. A webcast and conference call will follow at 4:30 p.m. ET. This session will provide insights into the company's performance, focusing on critical reagents for drug therapies and diagnostics. The company is known for its agility in delivering custom products for bioprocessing and molecular diagnostics.

Alpha Teknova (Nasdaq: TKNO) announced preliminary unaudited revenue for Q4 2021 of $10.0 to $10.1 million, including approximately $0.5 million from Sample Transport. Excluding this, revenue ranges from $9.5 to $9.6 million, marking a 25% increase year-over-year. Despite this growth, total revenue reflects a 1% decline compared to Q4 2020. The company will present its detailed financials around March 15, 2022, and will participate in investor conferences on March 9 and March 23, 2022.

Alpha Teknova, a key provider of critical reagents for biopharmaceuticals, will participate in the BTIG MedTech, Digital Health, Life Science, and Diagnostic Tools Conference from February 15-17, 2022. The company's President, Stephen Gunstream, and CFO, Matt Lowell, will host a virtual fireside chat on February 17 at 1:00 p.m. ET. They will discuss company highlights, market trends, and growth drivers. Teknova specializes in custom products for bioprocessing, offering high-quality reagents for applications like cell and gene therapy.